医学
乳腺癌
全身疗法
疾病
肿瘤科
脑转移
放射治疗
癌症
曲妥珠单抗
内科学
前瞻性队列研究
重症监护医学
转移
作者
Matthew N. Mills,Whitney King,Aixa Soyano,Yolanda Piña,Brian J. Czerniecki,Peter Forsyth,Hatem Soliman,Hyo S. Han,Kamran A. Ahmed
标识
DOI:10.1007/s11060-022-03977-x
摘要
Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal disease (LMD). Improvements in systemic therapy have translated to improved survival for patients with HER2-positive BCBM and LMD. However, the optimal management of these cases is rapidly evolving and requires a multidisciplinary approach. Herein, a team of radiation oncologists, medical oncologists, neuro-oncologists, and breast surgeon created a review of the evolving management of HER2-positive BCBM and LMD. We assess the epidemiology, diagnosis, and evolving treatment options for patients with HER2-positive BCBM and LMD, as well as the ongoing prospective clinical trials enrolling these patients. The management of HER2-positive BCBM and LMD represents an increasingly common challenge that involves the coordination of local and systemic therapy. Advances in systemic therapy have resulted in an improved prognosis, and promising targeted therapies currently under prospective investigation have the potential to further benefit these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI